Brainstorm Cell Therapeutics Inc BCLI:NASDAQ

Last Price$3.68NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/06/21

Today's Change+0.35(10.51%)
Bid (Size)$3.14 (1)
Ask (Size)$4.00 (1)
Day Low / High$3.23 - 3.71
Volume371.8 K
 

View Biotechnology IndustryPeer Comparison as of 12/06/2021

 

Brainstorm Cell Therapeutics Inc ( NASDAQ )

Price: $3.68
Change: +0.35 (10.51%)
Volume: 371.8 K
4:00PM ET 12/06/2021
 
 

AstroNova Inc ( NASDAQ )

Price: $17.16
Change: +1.28 (8.06%)
Volume: 33.1 K
4:00PM ET 12/06/2021
 
 

ICAD Inc ( NASDAQ )

Price: $6.70
Change: -0.35 (4.96%)
Volume: 328.8 K
4:00PM ET 12/06/2021
 
 

Immersion Corp ( NASDAQ )

Price: $5.64
Change: -0.07 (1.23%)
Volume: 5.3 K
4:00PM ET 12/06/2021
 
 

Iteris Inc ( NASDAQ )

Price: $4.44
Change: +0.01 (0.23%)
Volume: 147.6 K
4:00PM ET 12/06/2021
 

Read more news Recent News

Brainstorm Cell Therapeutics Chief Financial Officer Preetam Shah Plans to Resign at August End
5:24PM ET 8/25/2021 MT Newswires

Brainstorm Cell Therapeutics (BCLI) said late Wednesday Chief Financial Officer Preetam Shah has notified the company of his intention to resign, effective...

Sector Update: Health Care Stocks Still Hanging On To Wednesday Gains
3:57PM ET 3/24/2021 MT Newswires

Health care stocks were moderately higher ahead of Wednesday's close, with the NYSE Health Care Index rising 0.4% while the SPDR Health Care Select Sector...

Sector Update: Health Care Stocks Still Hanging On To Wednesday Gains
1:27PM ET 3/24/2021 MT Newswires

Health care stocks were moderately higher this afternoon, with the NYSE Health Care Index rising 0.4% while the SPDR Health Care Select Sector ETF also was...

Sector Update: Health Care
1:02PM ET 3/24/2021 MT Newswires

Health care stocks were higher in afternoon trade, with the NYSE Health Care Index and the SPDR Health Care Select Sector ETF rising 0.4% each on...

Company Profile

Business DescriptionBrainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ. View company web site for more details
Address1325 Avenue of Americas
New York, New York 10019
Phone+1.201.488.0460
Number of Employees31
Recent SEC Filing11/15/202110-Q
Chief Executive OfficerChaim Lebovits
President & Chief Medical OfficerRalph Z. Kern
Chief Operating Officer & Executive Vice PresidentDavid Setboun
Chief Financial Officer & ControllerAlla Patlis

Company Highlights

Price Open$3.32
Previous Close$3.68
52 Week Range$2.75 - 8.14
Market Capitalization$133.5 M
Shares Outstanding36.3 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.88
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-94.92%

Analyst Ratings as of 11/16/2021

Buy
1
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset